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Scientific environment  
As many as 17 candidates have accomplished their PhD degree at the Norwegian 
Arthroplasty Register (NAR) since its initiation in 1987. I have carried out my thesis in this 
environment, using the NAR database. Furthermore, I had access to the large dataset of 
the Nordic Arthroplasty Register Association (NARA), in which data from hip arthroplasty 
registers from Denmark, Finland, Norway and Sweden are merged. 
This project was jointly financed by the Western Norway Regional Health Authority, the 
Department of Orthopaedic Surgery at Haukeland University Hospital and the Jan A Pahle 
Foundation.  
The present thesis is included in the PhD programme at the Department of Clinical Science 
(K2), Faculty of Medicine and Dentistry, University of Bergen, Norway. 
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Abstract 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease which primarily 
affects and damages synovial joints. Patients with RA will therefore often undergo joint 
replacement surgery. Infections after such prosthetic joint replacements are rare but 
feared complications. RA patients are more susceptible to infections in general and the use 
of modern aggressive immunosuppressive treatment, such as TNF inhibition (from around 
the year 2000), may have increased this risk for infection. We have used data from the 
Norwegian Arthroplasty Register (NAR) from 1987 until 2008 (Paper I) and from the much 
larger database of the Nordic Arthroplasty Register Association (NARA) from 1995 to 2010 
(Paper III) to compare the risk of revision for infection in and over time for RA and 
osteoarthritis (OA) patients.  
The risk of revision for infection was 1.6 times increased in total knee replacements (TKRs) 
for RA patients compared to OA patients (Paper I). In total hip replacements (THRs) we 
found a 1.3 times higher risk of revision for infection in RA compared to OA (Paper III). We 
concluded that there was a higher risk of revision for infection in RA than in OA patients. 
For TKRs there was no increase in the risk of revision for infection in RA or in OA patients 
after the year 2000. In the Norwegian study (Paper I) the incidence of revision for infection 
of THRs was higher in the period 2001-2008 than in the period 1987-2000. However the 
increase affected RA and OA patients to the same degree. In the Nordic study (Paper III) 
the relative risk for RA patients compared to OA patients was increased in the latter period 
(2002-2010). This coincides with the introduction of TNF inhibitors in the medical 
treatment of RA. Similarly conflicting results are also found in the literature. 
From 5-6 years postoperatively, the risk of revision for infection was increased in RA 
compared to OA in TKRs and THRs (Paper I). Furthermore, we found a higher risk during 
the first three months and from around 8 years postoperatively in antibiotic-loaded 
cemented prostheses in RA-patients (Paper III), while no significant difference in the risk of 
infection for revision was found when comparing RA and OA patients with uncemented 
THRs. We conclude that the increased risk for late infections in RA is primarily seen for 
prostheses fixed with antibiotic-loaded cement. 
Staphylococcus aureus (S. aureus) has been reported to be the most important causative 
bacteria in prosthetic joint infection (PJI) in RA. In addition, RA patients are by many 
authors considered to represent a high-risk group in terms of acquiring infections with 
bacteria of potentially oral or dental origin. In Paper II we compared the bacterial findings 
of infections leading to revision in THRs in RA patients with OA patients, based on data 
from the NAR. We identified 49 infection episodes in 37 RA patients and compared the 
bacterial findings with 269 infection cases in 255 OA patients. No difference in bacterial 
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findings between RA and OA was found and thus we could not confirm the higher 
incidence of S. aureus in RA reported previously. Bacteria of potentially odontogenic origin 
were not found in RA patients but were found in 4% of OA patients and based on our study 
we could not confirm that RA patients are high-risk patients for infection with bacteria of 
oral or dental origin.      
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I Introduction and background 
1 Rheumatoid Arthritis 
1.1 RA and total joint replacements 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease which particularly 
affects the joints. The synovial involvement ultimately leads to the destruction of cartilage 
and bone in these joints. Around 1-2% of RA patients needed at least one large joint 
replacement per year of follow up in the pre-biological agent era (before the year 2000) [1-
4], and around 25% of all RA patients within 16-20 years of observation [5, 6].                                                   
The need for joint replacement surgery and also other types of disease-specific surgery 
such as synovectomies in RA seems to be declining [7, 8]. The more aggressive and 
meticulous use of conventional disease-modifying anti-rheumatic drugs (DMARDs) and the 
introduction of biologic medication may account for this [8].                                                                                  
The Nordic arthroplasty registers have shown, in different time periods, that between 15% 
and 3% of all primary total joint replacements in hips and knees were performed due to RA 
[9-15].  
1.2 Infection in RA 
RA patients are more prone to infections than the general population [16, 17] and this was 
already the case in the pre-steroid era [18]. The risk of developing infection in RA was 
estimated in one report to be twice the risk in non-RA subjects [16]. The higher 
susceptibility to infections might be explained by a primary disturbance of the 
immunological system in RA, an acquired impairment of the immune response, or a 
decrease in the resistance to infections which may occur in any chronic disease [18]. 
Among the sites with the highest infection risk were skin and soft tissue and bone and 
joints [16]. Infections in the bone and joints may also be attributed to local destruction of 
the normal anatomy leaving the joints more prone to infection. Glucocorticoids, which 
were introduced in 1949, have been shown to increase the risk of infection, for both 
infection-related hospitalizations and less serious infections [17, 19-22]. The risk is 
dependent on the duration of steroid use and the dose. The other non-biologic DMARDs 
have not with certainty been shown to increase the infection risk [22]. Age, comorbidities 
and disease activity are also regarded as risk factors for infection in RA [23, 24].  
1.3 TNF-Dinhibitors  
Tumour necrosis factor alpha (TNF-D is a central mediator in the normal inflammatory 
cascade. This pro-inflammatory cytokine is heavily involved in the immune system, and 
blocking TNF-D receptors not only reduces inflammation but is responsible for an immune 
suppressive effect.                                                                         
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TNF-Dinhibitors were first licensed for clinical use in 1998. In Norway they were 
introduced in 1999. The first three agents approved for treatment of RA were Infliximab 
(RemicadeR), Etanercept (EnbrelR) and Adalimumab (HumiraR). At present, 5 different 
agents are frequently used in this patient group, and recently the first biosimilar version of 
Infliximab  was taken into clinical use. TNF-Dantagonists have been shown to slow the 
radiological progression of RA [25, 26]. Decreased disability and improved quality of life are 
other important effects of these drugs, and patients also described positive overall effects 
[27]. The use of TNF-Dinhibitors has steadily increased since their introduction [28]. One 
study reported that in 2005 22% of RA and psoriatic arthritis patients were treated with 
TNF-Dinhibitors in Norway [29]. 
1.4 TNF-Dinhibitors and infection in RA   
Because of the immune suppressive effect of the TNF-Dinhibitors, the risk of serious 
infections has been a concern. A focused systematic review of the literature on the risk of 
infection due to TNF-D inhibitors was recently published [30]. Some observational studies 
have shown no increase in infection risk [31-37], while other such studies have revealed a 
clear increased risk of infection [38-42]. Conflicting results have also been reported in 
meta-analyses; some reported no increased risk of infection [43-45] whereas others 
showed an increased risk [46-48]. Relevant for orthopaedic surgery is the fact that some 
reports suggest a higher risk for skin and soft tissue infections [49] or septic arthritis in 
native joints [31] for patients using TNF-Dinhibitors. Others have pointed out that the risk 
of infection is highest in the first period after initiation of the TNF-Dantagonist use [32, 34, 
39, 49]. Interestingly, the immune suppressive effect of anti-TNF-Dagents is not limited to 
the possible increased occurrence of infection, but also to a potential deterioration of an 
already existing infection. The presence of any active infection is therefore a 
contraindication to start anti-TNF-Dtreatment [30].                                              
2 Prosthesis-related infections 
2.1 Prosthetic joint infections 
A prosthetic joint infection (PJI) is a dreaded complication after joint replacement surgery. 
It occurs in 1-2% of all primary total hip and knee replacements [50-52]. The consequences 
of PJI for the patient are frequent repeat surgeries with the removal or exchange of part(s) 
or the total prosthesis. This is associated with a decline in joint function, prolonged 
hospital stay, and extended use of potentially toxic and antimicrobial resistance-
encouraging antibiotics. In addition, the costs of the treatment to society are considerable. 
Earlier reports estimated the costs to be more than $50,000 per infection episode [53-56]. 
Compared to an uneventful primary total knee replacement the costs were calculated to 
be 3-7 times as high [55, 57]. Cost-effective perioperative preventative strategies are 
therefore desirable [58]. 
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2.2 Classification of PJI   
Prosthetic joint infections are caused by bacteria which reach the prosthetic material by 
entering the surgical wound during or directly after surgery. Alternatively, bacteria from a 
distant source are transported by the bloodstream to the implant (haematogenous seeding 
or blood-born infection). This may occur at any time after surgery. Classification of 
prosthesis-related infections may therefore be done according to the type of 
bacteria/virulence (e.g. low-grade) or according to the pathway of bacterial entry 
(postoperative versus haematogenous). Other systems classify according to the time from 
surgery or infection symptoms to diagnosis. These classifications are preferred by many 
clinicians because they aid in treatment decisions. A widely used system is named after 
Coventry [59] and divides the infections into early (0-3 months after surgery), delayed (3-
24 months) and late (after 24 months) infections. More recently, possibly due to the 
increase in revision surgery and changes in treatment modalities (e.g. Debridement, 
Antibiotics and Implant Retention (DAIR)), Tsukayama’s classification has become popular 
[60]. In this classification, an infection with the onset fewer than 4 weeks after surgery is 
called an ‘early infection’. It seems that the eradication rate with different treatment 
modalities largely depends on the duration of the infection. Therefore, the duration of 
symptoms has become an important factor in some newer attempts to classify prosthetic 
joint infections [61, 62].  
2.3 Definition of PJI, SSI and revision for infection     
Prosthesis-related infections include all deep infections after prosthetic joint replacement 
and the definition is wider than the true PJI. Different definitions for PJI exist [50, 63, 64] 
(Appendix I). One definition of PJI is the deep incisional (or organ/space) surgical site 
infection (SSI) (Appendix II). An SSI is a surgical wound infection occurring within the first 
postoperative year after a joint replacement and one distinguishes between superficial 
(incisional), deep (incisional) and organ/space SSI [65, 66]. The concept of SSI is mainly 
used in hospital infection surveillance. A superficial SSI gives a 35-fold increased risk for a 
PJI [63]. In this thesis we used revision for infection as the endpoint in the survival 
analyses. Revision was defined as the surgical removal or change of parts or the whole 
implant. Deep infection as the reason for revision was determined by the surgeon and 
reported immediately after surgery to the NAR, based on pre- and peroperative evaluation. 
Infections that were treated with minor soft tissue surgery or not surgically revised were 
not included in the study. Therefore the true incidence of prosthetic joint infections would 
be higher than that reported in our studies.  
2.4 Late infections 
The majority (around two-thirds) of prosthetic joint infections occur in the first two years 
after the index joint replacement [58, 67, 68]. The literature on prosthetic joint infections 
is consequently mostly focused on this period. Late infections are generally defined as 
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infections which appear more than one to two years after the index operation [59-61]. 
Although low-virulent infections acquired at the index surgery may present many years 
after the operations, the majority of these late infections are probably caused by 
haematogenous seeding. Haematogenous infections seed from distant origins like the skin, 
teeth, urinary and respiratory tract [67]. RA has been shown to predispose for 
haematogenous infections [69-71], and the diagnosis of RA is a risk factor for late infection 
[72]. Little is known on the potential influence of RA medication on the occurrence of late, 
haematogenous prosthetic joint infections.       
2.5 Risk factors for PJI 
Various patient-related risk factors for PJI after primary hip and knee joint replacement 
surgery have been found, such as systemic malignancy, rheumatologic disease, obesity 
(BMI>40), coagulopathy, preoperative anaemia, comorbidity (ASA>2), immunosuppression, 
cardiovascular disease, excessive anticoagulation (INR>1.5) and diabetes mellitus [68, 73-
75]. Most of them refer to the risk of acquiring postoperative infections. Rheumatoid 
arthritis is generally accepted as a patient-related risk factor for PJI. In TKRs the evidence 
for this is solid [14, 75-77] with a reported infection rate in RA 2-4 fold that of OA patients 
[78]. For THRs, however, the literature is conflicting [9, 79]. There are also conflicting 
reports regarding populations which included a combination of TKRs and THRs [63, 72, 80, 
81]. 
2.5.1 Nasal carriage of S. aureus as a risk factor for SSI 
Carriage of S. aureus has been shown to be a risk factor for SSIs in general [82, 83]. In the 
majority of cases, the infecting S. aureus in SSIs is transmitted endogenously [66, 84]. 
Elimination of S. aureus organisms from the nares in nasal carriers with a 5 day 
preoperative course of intranasal mupirocin and a chlorhexidine total body wash to 
decolonize the skin was, in a well-designed trial, found to reduce the frequency of SSIs 
[85]. A positive effect was also shown in a smaller study of total joint arthroplasty surgery 
[86, 87], while other earlier reports have been conflicting [88-90]. The routine use of 
screening for nasal carriage and a mupirocin (and chlorhexidine soap) course in nasal 
carriers ahead of total joint replacement surgery, is therefore still not recommended. The 
number of carriers of S. aureus, oral and nasal, has been shown to be higher in people with 
RA than in healthy adults [91-93] and one report revealed that as much as 37% of the PJIs 
in RA were caused by S. aureus [54]. Consequently, RA patients could be a subgroup that 
would benefit from preoperative screening and treatment.  
2.5.2 Dental intervention as a risk factor for late PJI 
It has been suggested that dental procedures may be a risk factor for late PJI. Transient 
bacteraemia during dental work and consequent haematogenous seeding to the artificial 
joint is thought to be the pathogenesis [67]. The potential association between dental 
intervention and PJI was proposed in 25 cases reported in the literature until 1995, which 
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suggests that it is a rather rare event [94]. It has been estimated that only 0.04-0.07% of 
PJIs are caused by oral bacteria [67, 95], but a more recent report suggested a much higher 
risk [96]. Importantly, there is a discrepancy between the bacterial findings in PJI and the 
bacteria supposed to cause bacteraemia during dental procedures. While staphylococci are 
predominantly (>50%) cultured in PJI, they are of no importance in bacteraemia during 
dental procedures [97]. Furthermore, in less than 10% of PJIs the cultured bacteria are of 
odontogenic origin [98] contrasting with more than 40% in infective endocarditis, where 
antibiotic prophylaxis against these odontogenic bacteria is well-established [94].  
Over three decades the prophylactic use of antibiotics before dental intervention has been 
a subject of discussion in the literature for dentists, orthopaedic surgeons and infectious 
disease specialists. A review of all English, German and French language literature 
evaluated 144 publications on this topic [99] and the authors concluded that PJIs due to 
haematogenous spread following dental work are very rare and that the scientific rationale 
for antibiotic prophylaxis at best is very weak. Furthermore, they stated that the use of 
perioperative antibiotic prophylaxis in selected, high-risk patients is based ‘more on fear 
than on science’. A recent study by Berbari [100] found no increased risk of PJI after dental 
interventions and no statistically significant reduction of PJI after using antibiotic 
prophylaxis targeting odontogenic microbes. Analyses of the high-risk subgroups (e.g. RA) 
showed that dental procedures were not a risk factor for PJI in any of the subgroups.                                       
A review from 2010 focused on the potential role  of staphylococci originating from the 
mouth as  cause of PJI after dental interventions [101]. The conclusion was to follow the 
preceding AAOS/ADA 2003 recommendations [102]. Here RA patients are considered high-
risk patients who should receive antibiotic prophylaxis in high-risk dental procedures. 
Somewhat surprisingly, they recommend some non-staphylococcal agents (e.g. amoxicillin) 
in cases of prophylaxis.                                                                                                                                                    
Various national guidelines and different recommendations exist [99, 103-112]. Whether 
all RA patients with artificial joint replacements should receive antibiotic prophylaxis 
before dental interventions is still unclear. Our study in Paper II may contribute to this 
discussion in Norway. 
2.5.3 RA medication as a risk factor for SSI 
2.5.3.1 Corticosteroids and synthetic DMARDs  
Corticosteroids have a negative influence on normal wound healing. They cause 
disturbance of the angiogenesis, collagen production and reepithelialisation of dermal 
wounds [113]. There is also a reduction of the neutrophil chemotaxis. The clinical 
consequences of these effects include delayed wound healing, dehiscence of the incision 
site and wound infection [114]. The magnitude of the problem seems to depend on the 
duration of use and the doses of the corticosteroids [17, 20]. It is not known at which dose 
(daily or cumulative) these anti-proliferative effects have clinical relevance [115]. There is 
scant knowledge of perioperative complication rates and corticosteroid usage in 
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orthopaedic surgery. Of four different studies, only one reported an increase in 
postoperative wound infection rate [116-119]. The other three studies were small, the 
corticosteroid dosage was generally low, there were different indications for corticosteroid 
use as well as different patient populations, and various surgical procedures were included 
[120]. The authors of a recent review of perioperative care for RA patients, stated that 
“prednisone is associated with one of the highest overall infection rates, far exceeding the 
risk associated with most conventional DMARDs and biologics” [121]. It is uncertain 
whether this may be extrapolated to the setting of orthopaedic surgery and joint 
replacement surgery.                                                                                                                                            
Of the synthetic disease modifying anti-rheumatic drugs (DMARDs), Methotrexate is the 
most commonly used in RA. Methotrexate inhibits leukocyte chemotaxis [113] and also 
seems to influence various immune mechanisms without completely eliminating them 
[115]. A wound infection may arise as a postoperative complication in patients taking 
Methotrexate [113], but most available studies have shown little to no effect of 
Methotrexate on postoperative complication rate after orthopaedic surgery. In a large 
prospective randomized trial including 388 patients, no increased infection or wound 
complication rate was found after orthopaedic surgery in patients continuing 
Methotrexate compared to those who withheld Methotrexate perioperatively [122]. Of the 
numerous retrospective and prospective studies evaluating the impact of Methotrexate on 
surgical complications [121], only two small studies (including 13 and 19 patients) came to 
a different result [123, 124]. Based on these findings, more recent literature advocates the 
continuation of Methotrexate perioperatively [120, 121]. However, modern RA treatment 
using the “treat to target” and tight control principle involves increasingly high doses of 
Methotrexate, often in combination with corticosteroids and/or other DMARDs [8, 120]. 
Future research will possibly show the influence on the infection risk.                                                              
With regard to other commonly used DMARDs including sulfasalazine (SalazopyrinR), 
hydroxychloroquine (PlaquenilR), leflunomide (AravaR), and azathioprine (ImurelR), research 
addressing adverse surgical events in association with these drugs is insufficient but in 
general, continuation perioperatively seems reasonable [121].                     
2.5.3.2 TNF-D inhibitors as a risk factor  
As described in Section 1.4, the risk of infection is of particular concern as a side effect of 
TNF-D inhibitors. The literature addressing anti-TNF-D treatment as a risk factor for 
infection after joint replacement surgery in RA is conflicting [125-134] (Appendix III). Some 
of these studies are clearly underpowered to detect a difference in a rare complication 
such as PJI. The other studies are difficult to compare since a variety of orthopaedic 
procedures with different baseline infection risks are included and the outcome measures 
are not uniform. In addition, SSI, which is a commonly used outcome in some of these 
studies, is not validated for joint replacement surgery [135]. Consequently, these studies 
are unable to conclude as to whether anti-TNF treatment is a risk factor for infection after 
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total joint replacement surgery in RA patients. Because of the persistent concerns 
regarding the safety of anti-TNF treatment, most guidelines recommend the 
discontinuation of anti-TNF treatment perioperatively [136-138]. 
2.5.4 Antibiotic-loaded cement as a risk factor for late PJI in RA 
Antibiotic-loaded cement in combination with antibiotics systemically has been shown to 
provide the best survival of the implant in primary THR surgery [139-141]. Furthermore, 
the risk of revision for infection was higher in THRs fixed with cement without antibiotics 
than in uncemented THRs and THRs fixed with antibiotic-loaded cement [139, 141]. In 
Scandinavia almost all cemented primary THRs are performed with antibiotic-loaded 
cement (The Danish Arthroplasty Register, The Norwegian Arthroplasty Register and The 
Swedish Arthroplasty Register).                                                                                                                                     
The release dynamics of antibiotics from the cement is not clear, but it is probably a 
combination of a surface and bulk phenomenon [142]. Little is known about the duration 
of the prophylactic antimicrobial effect of the antibiotics in cement. It varies in the 
literature from days to several years  [143, 144]. Cement in itself, due to its surface 
properties, has shown increased bacterial adherence and colonization compared to 
polyethylene and metal [144, 145].                                                                                                                              
In RA there is a higher susceptibility to (late) haematogenous prosthetic joint infections 
than in non-RA [69, 71]. Inactive cement, after cessation of the elution of antibiotics, may 
reinforce this susceptibility to (late) prosthetic joint infection in RA.    
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II Aims of the projects 
Paper I 
To compare the risk of revision for infection after THRs and TKRs between RA patients and 
OA patients based on data in NAR 
To detect changes in the relative risk of revision for infection in THRs and TKRs over time 
for RA and OA patients 
To investigate the time from primary surgery to revision for infection in THRs and TKRs in 
RA patients and OA patients 
 
Paper II 
To compare the bacterial findings in infections leading to revision of THR in RA patients and 
OA patients 
To assess the incidence of S. aureus infections and compare this in RA and OA patients  
To compare the incidence of infections leading to revision of THR caused by 
microorganisms potentially of oral or dental origin in RA patients and OA patients 
 
Paper III 
To compare the risk of revision for infection after THRs in RA patients and OA patients in a 
large Nordic study population 
To evaluate any changes with time in the relative risk of revision for infection in THRs in RA 
and OA patients 
To investigate the time from primary surgery to revision for infection in THRs, and evaluate 
the revision risk of RA and OA patients with uncemented and antibiotic-loaded cemented 
THRs specifically  
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III Patients and methods 
1. Health registers  
The Nordic countries have long-standing traditions of high-quality national health 
registries. The use of personal identification numbers enables the merging of data between 
different registries and surveys. These health registers offer an unique opportunity to 
study diseases and treatment modalities in large unselected populations and over a long 
period of time. Results from registry research thus, in general, provide results which are 
generalizable to all patients (excellent external validity). The large number of patients 
included allow for the evaluation of rare events in uncommon diseases (such as PJIs in RA 
patients) which may be difficult to study in other research settings. Furthermore, the 
longitudinal design with unlimited follow-up time offers the possibility to study 
complications, adverse events of treatment or death occurring late in the disease course, 
when other studies have usually been terminated. In addition, register-based studies are 
comparatively inexpensive and most often clinically solid endpoints may be studied.                                        
However, some limitations should be mentioned. Due to the nature of these registries with 
continuous registration by a number of doctors/nurses involved in the treatment of 
patients, the number of variables must be limited and for research purposes, important 
variables may be lacking. Thus, one may have to investigate proxy variables which reflect 
the outcome of interest (such as arthroplasty surgery which reflects joint destruction in 
RA). Also, possible confounding factors are controlled for by the randomization in an RCT, 
while such factors must be adjusted for using statistical analyses in register-based studies. 
Only a limited number of potentially confounding factors are registered, and several 
factors that can skew the results may be unknown. In addition, some authorities are 
concerned about the privacy aspect of using these health register data for medical 
research.  
2. The Norwegian Arthroplasty Register (NAR) 
The Norwegian Arthroplasty Register (NAR) was initiated in 1987 as a national hip 
arthroplasty register. From 1994 knee arthroplasties and prosthetic replacements of other 
joints were also registered [10]. The NAR is a national quality register approved by the 
Norwegian Data Protection Authority. Furthermore, it represents the cornerstone of the 
National Centre of Competence for Joint Replacements approved by the Norwegian 
Ministry of Health in 2002.The NAR is owned by the Norwegian Orthopaedic Association 
and is an integrated part of the Department of Orthopaedic Surgery, Haukeland University 
Hospital. The main objective of the register has been to detect inferior implants, bone 
cements and procedures, rapidly or as early as possible after introduction. Data on the 
primary implantation and any subsequent revision surgeries of the same joint is collected 
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and linked for each individual patient. Revision is defined as a reoperation where a part, 
various parts or the whole implant are exchanged or removed. In the study periods in 
Papers I and II, minor soft-tissue procedures were not reported to the NAR.                                                         
The following information is, amongst other variables, reported to the register: any 
previous surgeries to the  joint, the date and laterality of the operation, whether the 
operation is a primary or revision operation, which joint was operated, the indication for 
surgery (diagnosis), all data on the prosthetic components and bone cement used, 
reason(s) for revision (e.g. deep infection), type(s) of revision, data on systemic antibiotic 
prophylaxis and prophylaxis against thrombo-embolism, the type of operating theatre, 
operation time, perioperative complications etc. The operating surgeon fills in the register 
form immediately after the operation and sends it to the NAR. The registration is not 
compulsory, but the completeness for primary total joint arthroplasties of the hip and 
knee, as well as revisions, was more than 90% [146, 147]. The completeness of registration 
for removal procedures (e.g. Girdlestone) was somewhat (20%) lower [147]. In Paper I we 
identified 108,786 primary total hip and knee joint replacements in patients with RA and 
OA operated from 1987 (1994 for knees) until June 2008 in the NAR database. For Paper II, 
the NAR was used to identify patients revised due to infected hip prostheses from 1987 
until October 2007. 318 revisions for infection in 292 patients with RA and OA were 
included in the study.    
3. The Nordic Arthroplasty Register Association (NARA)  
Acknowledging the importance of surveillance of joint replacement surgery, arthroplasty 
registers were established in a number of countries. The Danish, Finnish and Swedish hip 
arthroplasty registers were instigated in 1995, 1980 and 1979, respectively.  The similar 
health care systems and the use of personal identity numbers in Norway, Finland, Denmark 
and Sweden make it possible, logical and desirable to combine and compare the data in 
these national arthroplasty registers. In 2007 a collaboration of the registers, the Nordic 
Arthroplasty Register Association (NARA), was established [148, 149]. For our study in 
Paper III we defined a set of parameters where all the national registers were able to 
provide data: age, gender, laterality, diagnosis (e.g. RA), date of primary THR, type of 
fixation, type of bone cement cup/stem, date and reason of revision (e.g. deep infection) 
and date of death. In all registers, the definition of revision was surgical removal or 
exchange of part(s) of or the whole prosthesis. The completeness of data in the individual 
registers is high [15, 147, 150]. In Paper III we identified in the NARA 390,671 primary total 
hip replacements in RA and OA patients from 1995 to 2010. 
4. Bacterial findings in revised hip prosthesis 
We identified 1443 revisions for infection in the NAR from 1987 until October 2007. The 10 
hospitals performing most revisions for infection, with a total of 730 revisions, were 
visited. The medical records of these patients were systematically reviewed. Incomplete or 
missing data were found in 228 revisions. Of the remaining 502, only 287 revisions were 
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performed in OA (269) and RA (18) patients. To increase the number of revisions in RA 
patients, we obtained the medical data of another 31 revisions for infection in RA patients 
from several other hospitals than those originally visited and we extended the period for 
RA patients from 2007 until 2009. Thus we included 269 revisions (in 255 OA patients) in 
the OA group and 49 revisions (in 37 RA patients) in the RA group.  
5.  Methods 
A major focus of this study was to understand distinct features of patients with RA in the 
setting of arthroplasty surgery and risk for infection of the implant. We compared patients 
with RA and OA in all three studies (Papers I-III). The larger group of patients with OA 
served as a control group as general changes such as changes in operating theatres, 
treatment policy, antibiotic and thrombosis prophylaxis, would presumably be similar for 
both groups. Using a control group gave us the opportunity to put our findings and 
conclusions concerning RA patients in a certain perspective.  
In the NAR, patients who are dead or lost to follow-up due to emigration are registered 
and the follow-up period is terminated at the date of death or emigration. For missing 
data, staff of the registry contact the relevant staff at each hospital to complete the forms. 
Thus, all patients registered have complete data on the basic variables such as 
demography, date and cause of surgery, implant type, and revision. However, patients may 
be re-operated abroad without having emigrated, and such surgeries would not be 
registered. Furthermore, erroneous registration must be expected to occur occasionally, 
and the completeness of registration to the NAR, although very high, is not 100% and thus 
some operations may not be registered. Even so, we have no reason to suspect a 
systematic mis-registration or loss of patients or revisions.  
In Paper I we included 2,642 knees and 4,167 hips in the RA group, and 21,832 knees and 
80,325 hips in the OA group, all of which were primary procedures. Statistical analyses 
were performed separately for knees and hips. In Paper III 13,384 RA THRs and 377,287 OA 
THRs were included. In Studies I and III we compared the total risk of revision for infection 
in RA patients to OA patients. Furthermore, we evaluated the risk of revision for infection 
in two time periods (1987(1994)-2000 and 2001-2008 in Paper I, 1995-2001 and 2002-2010 
in Paper III), and we studied the timing of the revision procedure (early or late infections). 
The use of the much more extensive NARA database in Paper III meant that the group of 
RA patients revised due to infection was much larger (710 in Paper I and 2315 in Paper III). 
We were thus able to perform sub-analyses, mainly concerning the influence of the type of 
implant fixation on the risk of revision for infection. In addition, using a larger database 
and including patients from several countries improves the external validity of our findings. 
TNF-Dinhibitors were introduced in 1999/2000. From 2000 on, the use increased steadily 
[28], also among patients undergoing joint replacements [8]. Using 2000 (Paper I) and 2001 
(Paper III) as cut-off points, we divided the patients into one group (operated during the 
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later time period) in which a considerable proportion of the RA patients were treated with 
TNF-Dinhibitors and another group (operated during the earlier time period) in which 
none or very few received such treatment. RA and OA patients were compared within the 
two time periods (particularly in Paper III, Table 3) and the relation between the diagnostic 
groups was compared in order to evaluate a possible influence of the TNF-Dinhibitors on 
infection risk. By using the OA joint replacements as a control group, we controlled for 
most time-dependent changes, such as treatment policy, operating theatres and 
awareness, which may have influenced infection risk. Factors such as increased 
comorbidity (particularly diabetes and obesity) or an increased focus on prosthesis 
infection and thus possibly improved reporting of such revisions to the NAR, may have 
contributed to the overall increase in revisions for infections seen during the study period. 
However, since there is no reason for such factors to have influenced RA patients 
differently than OA patients, studying the difference in infection risk between RA and OA 
patients enables the detection of particular features or changes in the RA group. Of course, 
unknown factors may still have influenced one of the groups differently. This is an inherent 
problem with observational studies. 
Furthermore, we evaluated the time span from primary implantation until revision for 
infection and compared this between the two diagnostic groups (for knees and hips 
separately, Paper I ). In Paper III, in which the very large number of THRs from the NARA 
was studied, we compared this time span in RA and OA patients with uncemented THRs 
and with antibiotic-loaded cemented THRs. This was done to determine whether the 
fixation mode had an influence on the time from index operation until infection leading to 
revision. Every THR where antibiotic-loaded cement was used (both components cemented 
or hybrid/reverse hybrid) was included in the antibiotic-loaded cement group.                                                    
In Paper II we collected the bacterial findings of revisions for infection in RA and OA 
patients by visiting and reviewing the medical reports initially in a selection of 10 hospitals 
in which the highest number of revisions for infections had been performed. In patients 
having had more than one revision for infection in the same joint, data from all revisions 
were included. Since we were most interested in the occurrence of S. aureus (highly-
virulent bacteria), only one (or more) positive bacterial culture was considered sufficient to 
define it as causative for the infection. Usually, more than one positive culture is needed 
for the diagnosis of PJI [50, 62-64, 151]. The following bacteria were considered as 
potentially odontogenic bacteria (as defined by Berbari [100]): Viridans group streptococci, 
beta-haemolytic streptococci, Peptostreptococcus species, and streptococcus-like bacteria 
not further identified.  
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6.  Statistics  
We used the Student’s t-test to detect any group differences in normally distributed 
continuous variables (e.g. age, mean follow-up time). The Pearson chi-square test (and 
Fisher’s exact test in cases of low numbers) was used to test for group differences in 
categorical variables (e.g. gender, bacterial findings in RA/OA). Similar statistical methods 
were used in Papers I and III. In the survival analyses the start point was the primary 
arthroplasty. The follow-up time was estimated until the first revision for infection of the 
arthroplasty or until the patient was censored at death or emigration, at the end of the 
respective studies, or if the arthroplasty was revised for other causes than infection. The 
NAR is continually updated using Statistics Norway on patients who die or emigrate. 
Unadjusted survival analyses were performed using the Kaplan-Meier method [152]. To 
estimate the relative risk (RR) with 95% CI, Cox regression analyses with adjustment for 
age, gender, diagnosis, year of primary surgery (and fixation mode in Paper III) were 
performed [153]. We used an extended Cox model to estimate the (log) RR within different 
follow-up intervals. P-values lower than (or equal to, Paper III) 0.05 were considered 
statistically significant. The statistical analyses were performed using the statistical 
software programmes SPSS (SPSS, Chicago, IL), versions 15.0 (Paper I) and 20.0 (Paper III), 
and the statistical software package R [154].    
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IV Summary of Papers I-III 
Paper I 
Risk of revision for infection in primary total hip and knee arthroplasty in patients with 
rheumatoid arthritis compared to osteoarthritis. A prospective, population-based study 
on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register                                     
Johannes C. Schrama, Birgitte Espehaug, Geir Hallan, Lars B. Engesæter, Ove Furnes, Leif I. 
Havelin, Bjørg-Tilde S. Fevang 
Objectives: We compared the differences in risk of revision for infection, changes in risk 
over time and in time from primary surgery to revision for infection after THRs and TKRs, in 
RA patients and OA patients.   
Methods: In the Norwegian Arthroplasty Register, 6,629 and 102,157 primary total joint 
replacements in patients with RA and OA, respectively, were identified from 1987 (1994 for 
knees) until 2008. Survival analyses with revision due to infection as endpoint were 
performed using the Kaplan-Meier method for constructing survival curves and multiple 
Cox regression to calculate relative risk (RR) estimates for diagnosis, adjusted for age, 
gender and year of primary surgery. An extended Cox model was used to estimate RR 
within different follow-up intervals. 
Results: RA patients with TKR had 1.6 times higher risk of revision for infection than OA 
patients, while there was no difference in the THRs. In the THRs we found a higher risk of 
revision for infection from 2001 onwards, whereas the development for TKRs was the 
opposite. These time effects affected the RA and OA groups equally. The risk of revision for 
infection from 6 years postoperatively onwards was higher in RA patients. 
Conclusion: The overall risk of revision for infection after TKR was higher in RA patients. 
The risk of late infection leading to revision of the TKR and THR was higher in RA patients 
than in OA patients. After the year 2000, the relative risk of revision for infection in RA, 
compared to OA, remained unchanged.  
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Paper II 
 
Bacterial findings in infected hip joint replacements in patients with rheumatoid arthritis 
and osteoarthritis. A study of 318 revisions for infection reported to the Norwegian 
Arthroplasty Register                                                                                                                                         
Johannes Cornelis Schrama, Olav Lutro, Håkon Langvatn, Geir Hallan, Birgitte Espehaug, 
Håkon Sjursen, Lars B. Engesæter, Bjørg-Tilde Fevang  
Objectives: To detect the bacterial cause of infected THRs in patients with RA compared to 
patients with OA. 
Methods: 1443 revisions for infection were reported to the NAR from 1987-2007. The 10 
hospitals with the highest number of revisions for infections were visited and a total of 730 
revision records were systematically reviewed. For this study 269 infection episodes in 255 
OA patients served as control group. We identified 49 infection episodes in 37 RA patients 
from 1987-2009. The bacterial findings were obtained from the microbiological reports in 
the patients’ medical records. 
Results: The RA patients were, on average, 10 years younger than the OA patients and 
there were more females (70% vs. 54%). We found no difference in the bacterial findings in 
patients with RA and OA. A tendency towards a higher frequency of Staphylococcus aureus 
(18% vs. 11%) causing PJI was found in the RA patients compared to the OA patients. There 
were no bacteria of potentially oral or dental origin found in the RA patients, while we 
found these in 4% of the OA patients. 
Conclusion: The type of bacteria that were identified in patients with RA did not 
significantly differ from those in OA patients. Bacteria of potentially odontogenic origin 
were not found in infected THR in RA patients. 
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Paper III 
 
Increased risk of revision for infection in rheumatoid arthritis patients with total hip 
replacements. A study of 390,671 primary arthroplasties from the Nordic Arthroplasty 
Register Association                                                                                                                                     
Johannes Cornelis Schrama, Anne M Fenstad, Håvard Dale, Leif Havelin, Geir Hallan, Søren 
Overgaard, Alma B Pedersen, Johan Kärrholm, Göran Garellick, Pekka Pulkkinen, Antti 
Eskelinen, Keijo Mäkelä, Lars B Engesæter and Bjørg-Tilde Fevang 
 
Objectives: We studied the risk of revision due to infection and changes over time after 
primary THRs in patients with RA and OA during a 16-year period. Time from primary 
implantation to revision was compared between the two diagnostic groups. Uncemented 
THRs and those fixed with antibiotic-loaded cement were studied separately. 
                                                                                                                                                                                    
Methods: We identified 13,384 THRs in RA patients and 377,287 THRs in OA patients from 
1995 to the end of 2010 in a dataset of the NARA. Kaplan-Meier survival curves, with 
revision for infection as the endpoint, were constructed. Cox regression analyses were 
performed to calculate the RR of revision for infection adjusted for age, gender, fixation 
technique and year of primary surgery. An extended Cox model was used to estimate RR 
within various follow-up intervals in patients with uncemented THRs and THRs fixed with 
antibiotic-loaded bone cement.  
                                                                                                                                                                                  
Results: RA patients had a 1.3 times (CI 1.0-1.6) higher risk of revision for infection than OA 
patients. After 2001 the risk of revision for infection after THR increased more for RA 
patients than for OA patients. During the first 3 months and from 8 years postoperatively 
the risk of revision for infection was higher in RA patients with THRs fixed with antibiotic-
loaded cement than in OA patients with THRs similarly fixed.  
                                                                                                                                                                              
Conclusion: Overall, we found a slightly higher risk of revision for infection in RA patients 
than in OA patients, but this difference was only present after 2001. In antibiotic-loaded 
cement THRs the risk of early and late infections leading to revision was increased in RA 
compared to OA patients. In the uncemented THRs no statistically significant difference in 
risk of revision for infection between RA patients and OA patients was revealed.  
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V General discussion 
1. Overall risk of revision for infection in RA versus OA 
Paper I showed that the risk of revision for infection in TKRs was 1.6 times higher in RA 
than in OA patients (RR 1.6 (1.1-2.4)), while there was no difference in THRs when 
comparing RA and OA (RR 0.98 (0.7-1.5)). In Paper III we found a 1.3 times higher risk of 
revision for infection in THRs in RA compared to OA (RR 1.3 (1.0-1.6)). The discrepancy in 
the result in THRs between Papers I and III is difficult to explain. One explanation may be 
that the number of patients in Paper III is much greater which may enable the detection of 
smaller differences, and render them statistically significant. Alternatively, the results may 
indeed be different, possibly due to the inclusion of patients from four countries and/or by 
a slight difference in study periods (1987(1994) to June 2008 in Paper I and 1995-2010 in 
Paper III). For TKRs our findings confirm the findings of other authors [14, 75-77] describing 
an increased risk of revision for infection in RA patients. For THRs, however, the literature 
is conflicting [9, 79], which to some extent is illustrated by the difference in results in our 
Studies I and III. Thus, based on our studies as well as other previous studies, there is a 
higher general risk of revision for infection in RA patients compared to OA patients, but for 
THR, if present at all, this increased risk seems to be small and of uncertain clinical 
importance.   
2. Risk of revision for infection in two time periods 
The cut-off for the two time periods was quite similar in Paper I (2001) and Paper III (2002). 
In Paper I, the relationship between RA and OA patients in the risk of revision for infection 
in TKRs and THRs did not change over the whole study period. In Paper III we found no 
difference in revision for infections between RA and OA patients in the first period, but a 
difference became evident in the last period (RR 1.4 (1.0-1.8)). As mentioned above, and 
maybe to a larger extent in this case, the greater numbers included in Study III may explain 
the discrepancy in results between Papers I and III, as may the inclusion of an additional 
two and a half years of inclusion and follow-up with more RA patients potentially on 
aggressive immune-modulating therapy.        
In the following, I will focus on the findings in Paper III.  
Post aut propter (after this or on account of this)                                                                                                       
In the last period (2002-2010) the risk of revision for infection was higher in RA patients 
than in OA patients. This was not the case in the earlier time period (1995-2001). There are 
a few possible explanations for this finding. First, the relative increase in risk of revision for 
infection coincides with a change in the general treatment of RA. Over the last 5-10 years 
the ‘treat to target’ principle has been developed and implemented in the management of 
RA. This means a more aggressive medical treatment with initially frequent and regular 
follow-up and appropriate therapeutic adaptation aiming at rapid remission with low 
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disease activity [155]. Generally, higher doses of Methotrexate, corticosteroids and more 
often combination regimes have been used. This may have contributed to a greater 
susceptibility to infection in the last period.                                                                                                                  
Second, the immune-modulating TNF-Dinhibitors were introduced in the treatment of RA 
around 1999/2000. The use has increased steadily [28], also in patients undergoing total 
joint replacements [8]. Later, other biologic drugs have been introduced including 
rituximab (MabTheraR), abatacept (OrenciaR) and tocilizumab (RoActemraR). If a major 
negative impact of biologic treatment on infection risk had been present, there is reason to 
expect that it would have influenced the results markedly. A small increase in risk of 
infection leading to revision was indeed found during the last time period, in Paper III, 
which may indicate such an effect; however, the magnitude of the difference was small. 
Moreover, we did not have data on the use of biologics or other drugs and thus could not 
tell whether the patients with infected implants used biologics or not. Thus, our findings 
may have been due to other time-dependent factors that we were not able to identify 
from our registry dataset.  
Other possible factors that may have influenced the infection risk in RA patients during the 
last 10-year period could be that RA patients were treated differently from OA patients by 
the surgeons in the last period, for instance in the choice of antibiotic prophylaxis or 
fixation mode. However, one would rather expect such measures, if taken, to have the 
opposite effect on the results. Furthermore, there is no literature to support a general 
increase in disease severity in RA patients which could explain an increase in infection risk. 
On the contrary, some authors believe that the disease severity has become milder during 
recent years, although it is difficult to know whether such a change is due to improved 
treatment or to changes in disease features [156]. Increasing overweight in the population 
during recent years is well known, but there is no literature to support such a development 
to be greater in RA patients than OA patients. On the contrary, obesity is an important risk 
factor for developing OA. 
Thus, we believe changes in the medical treatment for RA to have been a major cause of 
this increase in risk of revision for infection in RA THRs during recent years. However, the 
magnitude of the increase was small and of limited clinical importance and based on our 
findings, we recommend continued close surveillance and additional studies to further 
illuminate this issue. 
3. Risk of early and late revision for infection  
In Paper I we evaluated the time from the primary TKR and THR until revision for infection. 
In the first postoperative year there was a trend towards a higher risk of revision for 
infection in RA compared to OA patients in the TKRs (RR 1.8 (0.9-3.4)). From 5-6 years 
postoperatively onward we found an increased risk of revision for infection in RA 
compared to OA in both the TKRs and THRs, with RR 5.4 (1.9-16) and RR 4.1 (1.6-11), 
respectively. This was statistically significant from about 7 years postoperatively, but the 
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gap between the risks in RA and OA patients started to appear at 5-6 years 
postoperatively.  
In Paper III we wished to study this observation more closely and we therefore analysed 
the time from primary THR until revision for infection in uncemented and antibiotic-loaded 
cemented prostheses separately. In the uncemented THRs we found a trend towards a 
higher risk in RA compared to OA throughout the follow-up period (the RR from 3 months 
to 2 years was 1.1 (0.6-2.2, p=0.72), from 2 years to 8 years 1.4 (0.6-2.9, p=0.44)) and 
longer than 8 years postoperatively 1.5 (0.3-6.8 p=0.62). In antibiotic-loaded cemented 
THRs a significantly higher risk in RA was revealed during the first three months 
postoperatively (RR 1.8 (1.1-3.0)) and from 8 years onward (RR 2.7 (1.2-6.3), Figure 1).  
Figure 1. Time from primary operation to revision for infection comparing RA to OA patients in Paper I, THRs 
and TKRs, and in Paper III, THRs inserted uncemented or with antibiotic-loaded cement. 
 
 
Early infections                                                                                                                                                                  
The trend to an increased risk of revision for infection in the early postoperative period in 
TKRs (1 year in Paper I) and THRs with antibiotic-loaded cement (3 months in Paper III) in 
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RA compared to OA can be explained by higher rates of wound infection in RA [157]. The 
lack of this finding in THRs in Paper I and in uncemented THRs in Paper III may be explained 
by a combination of a general higher risk of infection leading to revision in replacements of 
knees than in replacements of hips when comparing RA to OA (Paper I) and by the lower 
numbers in Paper I than in Paper III and therefore greater uncertainty of the results. There 
was no significant difference in risk of revision for infection between RA and OA in 
uncemented THRs in the first 3 months (RR 0.4 (0.1-1.8)), whereas there was a significantly 
higher risk in RA than in OA in antibiotic-loaded cemented THRs (RR 1.8 (1.1-3.0)). This 
difference in findings between uncemented and antibiotic-loaded cemented prostheses 
found in Paper III may be explained by a possible selection of low risk (less comorbidities, 
younger, etc.) RA patients for the uncemented THRs. 
Late infections                                                                                                                                                         
After the early postoperative period (1 year in Paper I and 3 months in Paper III) the curves 
for RA patients show a similar course except in the uncemented THRs. In the majority of 
the total joint replacements in Paper I, antibiotic-loaded cement was used. In Norway only 
15-20% of THRs and even fewer TKRs are uncemented [158]. This may explain why the 
curves of THRs and TKRs in Paper I are so similar to the cemented curve in Paper III. The 
course of these curves after the first postoperative year is characterized by a lack of 
difference between the two diagnostic groups the first 5-6 years followed by an increasing 
difference between the risks with time. This finding could be caused by an initial protective 
effect of the antibiotics in the cement lasting somewhat longer than 5 years but shorter 
than 10 years, which was also found by Josefsson [143]. After these 5-8 postoperative 
years the elution of the antibiotics and the protective effect cease. Not only the extra 
volume but also the surface properties (bacterial adherence/colonization) of the now 
inactive bone cement may reinforce the already higher susceptibility for haematogenous 
infections in RA patients possibly leading to late infections causing revision. This may also 
explain the lack of increase in late infections in RA patients operated with uncemented 
prostheses, since there is no (initial) protection of the antibiotics, and no late adverse 
effect of the cement. The 95% CI for the uncemented THR RA curve is quite wide, 
indicating some uncertainty of the results. This should be kept in mind when interpreting 
the findings. Due to the low number of patients having cemented prostheses without 
antibiotics, no sub-analyses were performed for the RA versus the OA patients and we may 
not conclude any potential impact of such fixation in RA patients.   
4. Bacterial findings 
In Paper II we found no statistically significant difference in bacterial findings in PJIs in RA 
patients compared to OA patients. There was a trend towards a higher frequency of S. 
aureus in RA than in OA (18% vs. 11%) but we could not with certainty confirm the findings 
of Berbari who found 37% S. aureus in their study of THRs and TKRs in patients with RA 
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[54]. Bacteria of potential oral or dental origin (odontogenic) had an occurrence of 4% in 
OA, while in RA no such bacteria were found.  
A substantial part of the material, 31-37%, was culture negative. This is much higher than 
other authors have reported (2-18%) [64]. The reason for this may be the use of 
antibiotics, inadequate taking, handling and/or culturing of the samples or an incorrect 
diagnosis of infection. In our study staphylococci were found in more than half of the 
positive cultures, which has also been reported by others [50, 159]. We performed a prior 
statistical power analysis based on the study by Berbari [54], which is the largest study 
performed in RA patients (see Chapter VII, bacterial findings). This showed a sufficient 
power with the numbers of infection episodes in RA patients which were actually included 
in our study. However, we expected a higher incidence and a greater difference in the 
frequency of S. aureus between the two diagnostic groups than were eventually found. The 
study was therefore underpowered and unable to detect (small) differences, if present. 
Our findings should therefore be interpreted with this in mind. 
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VI  Conclusions 
 
Paper I 
The overall risk of revision for infection in TKRs was 1.6 times higher in RA than in OA 
patients. In THRs there was no difference in the risk of revision for infection between RA 
and OA patients.  
The risk of infection for RA patients relative to OA patients did not change after the year 
2000. 
In both the TKRs and the THRs the risk of revision for infection was higher in RA patients 
than in OA patients from 5-6 years postoperatively.  
 
Paper II 
We found no difference in bacterial findings from infected THRs in RA patients and OA 
patients. 
In RA patients we found a frequency of S. aureus of 18% and in OA patients 11%. This 
difference was not statistically significant. 
Odontogenic bacteria causing infection leading to revision were found in 4% of OA 
patients, while no such bacteria were found in RA patients.  
 
Paper III 
The overall risk of revision for infection in THRs was 1.3 times higher in RA patients than in 
OA patients. 
The difference in risk of revision for infection between RA and OA patients emerged after 
2001. In the period 1995-2001 no difference was seen. 
In patients having antibiotic-loaded cemented prostheses, the risk of revision for infection 
was higher in RA patients than in OA patients during the first 3 postoperative months and 
increasingly from 8 years postoperatively. 
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VII Methodological considerations 
Quality of data                                                                                                                                                                  
Studies I and III are register-based studies. These are prospective, observational (cohort) 
studies. The evidence level of such studies is inferior to randomized controlled trials (RCTs), 
which represent the gold standard in evidence-based medicine. A strength of our study is 
that we evaluate the occurrence of a rare event occurring in a relatively small diagnostic 
group of patients with THRs. Comparing the small RA group with a large control group (OA 
patients) over a long follow-up time was done to control for potential (time-dependent) 
confounders (e.g. changes in operating technique, operation theatres, pre-and 
postoperative procedures, threshold for operating older patients, awareness of prosthesis 
infections, diagnostics of infection, etc.). The studies thus offer a reasonably high internal 
validity.                                                                                                                                                                               
The end point (i.e. revision for infection) of the studies was solid, but the designation of 
deep infection as the cause for revision depended on the judgment by the individual 
surgeon based on preoperative and perioperative findings. The results of cultures taken at 
revision surgery were not available when the register form was completed. The precision 
of the diagnosis is therefore uncertain.                                                                                                                        
The numbers and completeness of the data are high in both studies, making our results 
generalizable in terms of setting and population. The external validity is therefore also 
high, at least in a Caucasian population. 
As mentioned above, the diagnoses registered in the NAR and NARA databases are made 
before the results of the tissue cultures from the surgery are ready. Therefore some 
patients will be erroneously diagnosed with infection and some infected cases will 
erroneously be diagnosed with aseptic loosening, pain alone or other diagnoses. 
Studying the influence of medication and fixation mode on the risk of revision for infection                              
The optimal study design for the evaluation of the influence of certain medication regimes 
on infection rates would be an RCT. However, a very large number of RA patients would 
have to be included in order to have sufficient power to detect differences of the rare 
event of PJI. The follow-up period would also have to be quite long. Similarly, for studying 
mode of fixation, a vast number of RA patients would have to be randomized to cemented 
or uncemented fixation. Such studies have not been performed, presumably because they 
would be extremely difficult, time-demanding and expensive to undertake. In addition, the 
allocation of RA patients into specific treatment regimens for a very long period of time 
may represent an ethical dilemma. The medication of RA is highly individualized and 
appointing patients into predetermined treatment regimens could lead to suboptimal 
treatment of some patients.  
Our register-based studies give information on the actual outcome in terms of revision for 
infection, in a large patient cohort followed for up to 21 (Paper I) and 16 years (Paper III). 
 34 
To study the influence of medication in RA on the risk of revision for infection in joint 
replacements more accurately, a future study could be based on a linkage of the 
Norwegian Prescription Database and the NAR. The Prescription Database has person 
identifiable data from 2007, which was not sufficient for the present studies, but can be of 
great interest in the future. 
 It would have been of interest to study the impact of fixation mode more closely. We did 
not find a statistically significant difference in the risk of revision for infection in RA 
patients compared to OA patients with uncemented THRs. Even with the use of the large 
NARA database, the number of RA patients having uncemented THRs was rather low (n = 
3,034). This caused our findings to be uncertain, as illustrated by the wide 95% confidence 
interval. However, in our study of around 3,000 RA patients and 83,000 OA patients with 
uncemented THRs, no difference in infection revisions was detected and we may conclude 
that, if present, a difference in risk between RA and OA patients must be small and 
probably clinically insignificant.  
Bacterial findings                                                                                                                                                                
The study in Paper II is a retrospective study and consequently did not have an optimal 
quality of data. A large number of infection episodes had missing or erroneous data (228 of 
730). Although not analysed, we had no reason to believe that these exclusions involved a 
selection bias. Furthermore, we performed a power analysis based on the findings of 
Berbari [54] who found 37% S. aureus in PJI in RA patients. Our number of infection 
episodes in RA and OA would achieve sufficient statistical power with a 20% difference in 
group proportions. In our present study we revealed only 18% S. aureus in RA versus 11% 
in OA. There thus were too few infection episodes in our RA patients to detect a 
statistically significant difference for S. aureus, if present. This represents a type II error. A 
type II error is the inability or failure to reject a false null hypothesis and is commonly 
caused by an insufficient number of observations. The probability of the type II error (β) is 
related to the power of the test (1-β). In other words, our finding of p-values in the non-
significant range can either reflect a lack of difference between the patient groups or that 
there are too few infection episodes to show such a difference, if existent. In conclusion, a 
new study with additional collection of data from the last 6 years will probably give a 
better chance to detect any differences, if present.   
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VIII  Clinical implications  
In addition to the obvious burden to the patient caused by repeat surgery, long-term 
antibiotic treatment and hospital stays, and often reduced function, prosthesis-related 
infections are associated with substantial costs for the health care system (Chapter I 2.1). 
Of additional concern in RA patients is the need to pause important anti-rheumatic medical 
treatment during the infection episode, often resulting in flares of the rheumatologic 
background disease, thus adding to the burden of prosthesis infection in RA patients. 
These factors as well as the higher risk of revision for infection after joint replacements in 
RA patients compared to OA patients make specific preventive strategies desirable.                                         
Preoperative considerations                                                                                                                                           
The preoperative care of the RA patient undergoing joint replacement surgery should 
include a strict evaluation of the patient’s medication, with particular focus on steroid 
therapy and biological agents. Most guidelines advocate the cessation of biologic drugs. A 
recent consensus group meeting (organized by orthopaedic surgeons) that dealt with 
periprosthetic infection proposed that all DMARDs including Methotrexate, biologic drugs 
and steroids should be discontinued prior to elective joint replacement surgery [151]. 
Furthermore, the disease activity of RA should be as low as possible when undergoing 
surgery. 
Prevention of early postoperative infections                                                                                                                
It has previously been shown that screening/selective decolonization will reduce the 
number of SSIs and that this procedure is cost-effective [160]. Furthermore, RA patients 
have a higher occurrence of nasal carriage of S. aureus than the non-RA population 
(Chapter I 2.5.1) and our study in Paper II showed a trend towards higher frequency of S. 
aureus in revisions for infection in RA than in OA patients. In addition, wound infection 
after joint replacement surgery appears more often in RA than in OA patients [157] and 
Berbari [63] showed that such SSIs represent a massive risk factor (RR=35) for PJI. 
Consequently, to prevent early infections, preoperative screening/selective decolonization 
of S. aureus could be considered introduced as a routine in RA patients. Preferably, this 
should be done in a clinical trial, although such a study might be difficult to accomplish due 
to the rareness of SSI.                                                      
Prevention of late haematogenous infections                                                                                                             
RA patients with indwelling prosthetic joint replacements are especially susceptible to late, 
haematogenous infections leading to revision. Specific preventive measures include 
adequate (and prompt) treatment of all respiratory, urinary, odontogenic and skin and 
soft-tissue (especially of the same extremity) infections in such patients. However, in 
general the occurrence of haematogenous late infections after seeding from remote 
infections is probably low [161].                                                                                                                                    
Based on our study in Paper II we are unable to conclude on whether to give routinely 
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prophylactic antibiotics before dental procedures in all RA patients with prosthetic joint 
replacements. Our Study II suggests that anti-staphylococcal antibiotics should be 
prescribed, if prophylactics are to be given. Individual evaluation of RA patients seems to 
be important [104] and is needed to determine the risk factors for infection. Immune-
suppressed, high-risk RA patients (e.g. with high disease activity, lingering use/high steroid 
dose, leukopenia, use of biologics, etc.) should be considered for antibiotic prophylaxis 
before dental procedures.                                                                                     
Microorganisms                                                                                                                                                               
Based on our findings in Paper II, where a high percentage of negative cultures was 
revealed, a focus on detection of the bacteria in the setting of revision surgery 
(perioperatively) seems to be needed. An ‘antibiotic holiday’ before taking samples, an 
adequate number of samples, optimal handling of the samples and mode and duration of 
culturing should be evaluated more strictly. 
Antibiotic-loaded cement                                                                                                                                                 
Paper III revealed a higher risk of revision for infection in THRs after 8 years postoperatively 
in RA compared to OA patients when antibiotic-loaded cement was used. However, no 
difference in the total risk of revision for infection was seen when comparing THRs with 
antibiotic-loaded cement to uncemented ones. In general, the use of antibiotic-loaded 
cement as the fixation mode in THRs is recommended in all high-risk patients to prevent 
PJIs [151]. Based on our findings, one should be aware that the risk of infection leading to 
revision increases slightly from 5-8 years onwards after implantation of a THR with 
antibiotic-loaded cement (or TKR (Paper I)) in RA patients compared to OA patients.  
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X Appendices 
Appendix I 
Definition of PJI (Berbari 1998, Del Pozo 2009) 
Presence of at least one of the following: 
1. Acute periprosthetic inflammation on histopathological examination 
2. Sinus tract communicating with the prosthesis 
3. Gross purulence in the joint space 
4. Isolation of significant amounts of the same microorganism from more than one cultures of 
joint aspirates 
 
Another proposal to define a Periprosthetic Joint Infection (Parvizi 2011) 
1. There is a sinus tract communicating with the prosthesis, or 
2. A pathogen is isolated by culture from at least two separate tissue or fluid samples 
obtained from the affected prosthetic joint, or 
3. Four of the following six criteria exist: 
a) Elevated serum erythrocyte sedimentation rate (ESR) and serum C-reactive 
protein (CRP) concentration 
b) Elevated synovial leucocyte count 
c) Elevated synovial neutrophil percentage (PMN%) 
d) Presence of purulence in the affected joint 
e) Isolation of a microorganism in one culture of periprosthetic tissue or fluid 
f) More than five neutrophils per high-power field in five high-power fields 
observed from histologic analysis of periprosthetic tissue at 400 times 
magnification 
PJI may be present if fewer than four of these criteria are met. 
 
A third definition of Periprosthetic Joint Infection (Parvizi 2013) 
1. Two positive periprosthetic cultures with phenotypically identical organisms, or 
       2.    A sinus tract communicating with the joint, or 
* Having 3 of the following minor criteria: 
a)  Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR)                                           
b)  Elevated synovial fluid white blood cell (WBC) count OR +change on leukocyte esterase test strip  
c)  Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%)                                                          
d)  Positive histological analysis of periprosthetic tissue                                                                                              
e)  A single positive culture 
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Appendix II 
Surgical Site Infection (CDC Definition) (Horan 1992, Skramm 2013) 
Superficial Incisional Surgical Site Infection 
Infection within 30 days after the operation and only involves skin and subcutaneous tissue of the 
incision and at least one of the following: 
1. Purulent drainage with or without laboratory confirmation, from the superficial incision 
2. Organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision 
3. At least one of the following signs or symptoms of infection: pain or tenderness, localised 
swelling, redness, or heat and the superficial incision is deliberately opened by the surgeon, 
unless the incision is culture-negative 
4. The diagnosis of superficial incisional SSI is made by a surgeon or attending physician 
 
Deep Incisional Surgical Site Infection  
Infection occurs within one year if implant (e.g. joint replacement) is in place and the infection 
appears to be related to the operation and the infection involves deep soft tissue (e.g. fascia, 
muscle) of the incision and at least one of the following: 
1. Purulent drainage from the deep incision but not from the organ/space component of the 
surgical site 
2. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the 
patient has at least one of the following signs or symptoms: fever (>380C), localised pain or 
tenderness, unless the incision is culture-negative 
3. An abscess or other evidence of the infection involving the deep incision is found on direct 
examination, during reoperation, or by histopathologic or radiologic examination 
4. Diagnosis of deep incisional SSI made by a surgeon or attending physician 
 
Organ/Space Surgical Site Infection 
Infection occurs within one year if implant (e.g. joint replacement) is in place and the infection 
appears to be related to the operation and the infection involves any part of the anatomy (e.g. 
organs and spaces) other than the incision which was opened or manipulated during an operation 
and at least one of the following: 
1. Purulent drainage from a drain that is placed through a stab wound into the organ/space 
2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space 
3. An abscess or other evidence of infection involving the organ/space that is found on direct 
examination, during reoperation, or by histopathologic or radiologic examination 
4. Diagnosis of organ/space SSI is made by a surgeon or attending physician 
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Appendix III 
Studies on influence of anti-TNF treatment on risk of infection after orthopaedic surgery 
 
 
Publication  Surgery Conclusions Notes 
Talwalkar (2005) Anti-TNF treatment 
with or without 
perioperative 
continuation 
Elective 
orthopaedic 
surgery 
Anti-TNF treatment  
without cessation 
didn’t increase the 
rate of infection 
No serious wound 
infections in any of 
the patients. 
Underpowered 
Wending (2005) Anti-TNF 
treatment, with or 
without 
continuation 
Mainly 
orthopaedic 
surgery 
Uninterrupted use 
of anti-TNF 
treatment didn’t 
increase the 
frequency of 
adverse events. 
No pyogenic 
infections. 
Underpowered 
Giles (2006) Anti-TNF naïve vs. 
anti- TNF treatment 
Elective 
orthopaedic 
surgery 
Association 
between early 
serious 
postoperative 
infections and anti-
TNF treatment 
 
Ruyssen-Witrand 
(2007) 
Anti-TNF treatment 
with or without 
perioperative 
continuation 
Elective and 
emergency 
orthopaedic 
procedures 
A trend of more 
postoperative 
infections when 
continuation 
Underpowered 
Den Broeder 
(2007) 
3 cohorts: anti-TNF 
naïve, anti-TNF 
treatment with and 
without 
continuation  
Elective 
orthopaedic 
surgery 
Continuation of 
anti-TNF treatment 
not an important 
risk factor for SSI  
Not powered to 
detect small 
differences in 
infection rates 
Gilson (2010) Case control,  Anti-
TNF treatment and 
PJI vs. non-PJI  
Total joint 
arthroplasty 
Increased risk of PJI 
with anti-TNF 
treatment 
Steroid use was a 
risk factor for PJI 
Kawakami (2010) Case-control, anti-
TNF treatment vs. 
conventional 
DMARDs 
Joint surgery Increased risk of SSI 
for major 
orthopaedic surgery 
in anti-TNF 
treatment 
Anti-TNF treatment 
was interrupted 
perioperatively 
Flare ups in 17.2% 
Suzuki (2011) Anti-TNF treatment 
vs. non-biological 
DMARDs 
Joint arthroplasty 
surgery and other 
orthopaedic 
surgery 
Increased risk of SSI 
for joint 
replacements in 
anti-TNF treatment  
Anti-TNF treatment 
was interrupted 
perioperatively 
Momohara (2011) Biological DMARDs 
vs. non biologic 
DMARDs 
TKR and THR Increased risk of 
acute SSI for 
THR/TKR in anti-TNF 
treatment 
 
Berthold (2013) Anti-TNF treatment 
with or without 
continuation  
Elective 
orthopaedic and 
hand surgery 
 
No increased risk of 
SSI with 
continuation of anti-
TNF treatment 
Historical control 
group 
